

Ophthalmology

Bespoke relationship-driven approach to deliver with world class capabilities

The PPD™ clinical research business of Thermo Fisher Scientific has extensive global experience in planning, implementing, accelerating and delivering ophthalmology clinical trials across a broad range of drug classes to help you overcome these challenges and advance your therapeutic development.

In the past five years, we've conducted: -



67+ ophthalmology trials



Involving 10,000+ patients



Across **2,700** sites around the world

Broad therapeutic experience across indications

We have experience across a broad range of indications, both anterior and posterior, including:

- Acute optic neuritis
- Age-related macular degeneration
- Cataracts
- Conjunctivitis

- Diabetic macular edema
- Diabetic retinopathy
- Dry eye
- Fuch's Dystrophy
- Inherited Retinal Disease
- Geographic atrophy Glaucoma/ocular hypertension
- Myopia
- Ocular/Uveal melanoma
- Presbyopia
- Retinal vein occlusion
- Retinopathy of prematurity
- Thyroid Eye Disease
- Uveitis

Strong site relationships

We leverage our network of Vestrum sites, key opinion leaders, and sites with known history to deliver excellent data to ensure optimal site selection and robust patient enrollment. Our established relationships with key ophthalmology sites drive efficient site selection and accelerate patient enrollment, ensuring your study progresses smoothly and efficiently.

Combining our enrollment solution with Vestrum sites and Al for imaging analysis creates synergy to reduce site burden and identify qualified patients.

Protocol optimization

Benefit from our deep expertise in ophthalmology combined with advanced data analytics and AI to optimize your study protocols. This integration of expertise and technology ensures precision in study design and execution, maximizing the potential for successful outcomes. Our protocol optimization approach is designed to enhance the accuracy and efficiency of your research, providing you with reliable and actionable results. We can demonstrate the expected attrition of each inclusion/exclusion criterion and how it will affect the patient pool by leveraging our proprietary retinal database and our data analysts, who are extensively trained in ophthalmology. This offering identifies any roadblocks to recruitment so that mitigations can be considered a prior rather than ad hoc during the study.

Agile delivery

We understand the dynamic needs of biotech companies and offer flexible collaboration models to meet those needs. Our agile approach allows us to adapt quickly to changes, ensuring your study remains on track. Our ability to make swift adjustments as needed ensures that your study can respond to evolving requirements without compromising on quality or timelines, providing you with the flexibility necessary in today's fast-paced research environment.

Quality and endpoint protection

Our highly trained Clinical Research Associates (CRAs) are dedicated to protecting study endpoints, ensuring data integrity and reliability throughout the research process. We maintain strong relationships with BCVA and imaging vendors, ensuring high-quality data collection and analysis, which is critical for ophthalmology studies. Our commitment to quality ensures that every aspect of your study is conducted with the highest standards of excellence.

Partnering with us means accessing a vast network of specialized ophthalmology sites and data, benefiting from cutting-edge protocol optimization using Al and data analytics, and experiencing our ability to adapt quickly to your needs, ensuring seamless study progression. Our unwavering focus on endpoint protection and high-quality data collection makes us the ideal partner for your vision research needs.

Global footprint: powering stability and scalability





PPD Turnover '24:
Clinical Overall – 12%
CRA – 13%
PL/CL – 9%

Learn more at thermofisher.com/ppd